| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Villanueva A. Hepatocellular Carcinoma [J]. N Engl J Med, 2019, 380(15): 1450-1462.
|
| [3] |
Pinato DJ, Guerra N, Fessas P, et al. Immune-based therapies for hepatocellular carcinoma[J]. Oncogene, 2020, 39(18): 3620-3637.
|
| [4] |
Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired[J]. Blood, 2009, 114(8): 1537-1544.
|
| [5] |
Chinai JM, Janakiram M, Chen F, et al. New immunotherapies targeting the PD-1 pathway[J]. Trends Pharmacol Sci, 2015, 36(9): 587-595.
|
| [6] |
Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells[J]. Sci Transl Med, 2013, 5(200): 200ra116.
|
| [7] |
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune Checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168.
|
| [8] |
Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial [J]. Lancet Oncol, 2020, 21(4): 571-580.
|
| [9] |
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
|
| [10] |
Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial [J]. Lancet Oncol, 2018, 19(7): 940-952.
|
| [11] |
王毅欣，胡宗涛，张永康, 等. PD-1治疗晚期原发性肝癌患者的安全性及临床疗效观察 [J]. 肿瘤防治研究, 2020, 47(4): 298-302.
|
| [12] |
Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): An open-label, multicentre, phase 1b study[J]. Lancet Oncol, 2020, 21(6): 808-820.
|
| [13] |
Lee DW, Cho EJ, Lee JH, et al. PhaseⅡ study of Avelumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib[J]. Clin Cancer Res, 2021, 27(3): 713-718.
|
| [14] |
Finn RS, Ikeda M, Zhu AX, et al. Phase Ⅰb study of Lenvatinib plus Pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970.
|
| [15] |
滕颖，丁晓燕，李文东, 等. 程序性细胞死亡受体1抑制剂联合仑伐替尼治疗晚期原发性肝癌的效果及不良反应[J]. 临床肝胆病杂志, 2021, 37(3): 606-610.
|
| [16] |
张雯雯，胡丙洋，韩骏, 等. PD-1抑制剂与多靶点酪氨酸激酶抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告[J]. 中华肝胆外科杂志, 2020, 26(12): 947-948.
|
| [17] |
韩春，叶斯斯，李娟, 等. 安罗替尼联合PD-1单抗(AK105)治疗13例晚期转移性肝细胞肝癌的疗效及安全性评价[J]. 解放军医学院学报, 2020, 41(9): 868-871.
|
| [18] |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
|
| [19] |
Casak SJ, Donoghue M, Fashoyin-Aje L, et al. FDA approval summary: Atezolizumab plus Bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma[J]. Clin Cancer Res, 2021, 27(7): 1836-1841.
|
| [20] |
Bang YJ, Golan T, Dahan L, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)[J]. Eur J Cancer, 2020, 137: 272-284.
|
| [21] |
Xu J, Shen J, Gu S, et al. Camrelizumab in combination with Apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phaseⅡ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
|
| [22] |
Rowshanravan B, Halliday N, Sansom DM. CTLA-4: A moving target in immunotherapy[J]. Blood, 2018, 131(1): 58-67.
|
| [23] |
Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol, 2013, 59(1): 81-88.
|
| [24] |
Yau T, Kang YK, Kim TY, et al. Efficacy and safety of Nivolumab plus Ipilimumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib: the CheckMate 040 randomized clinical trial[J]. JAMA Oncol, 2020, 6(11): e204564.
|
| [25] |
Tang C, Welsh JW, de Groot P, et al. Ipilimumab with Stereotactic ablative radiation therapy: phase results and immunologic correlates from peripheral T cells[J]. Clin Cancer Res, 2017, 23(6): 1388-1396.
|
| [26] |
Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3): 545-551.
|
| [27] |
Wong JSL, Kwok GGW, Tang V, et al. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors[J]. J Immunother Cancer, 2021, 9(2): e001945.
|
| [28] |
Singh A, Beechinor RJ, Huynh JC, et al. Immunotherapy updates in advanced hepatocellular carcinoma[J]. Cancers (Basel), 2021, 13(9): 2164.
|
| [29] |
Kudo M. Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti-PD-1/PD-L1 and anti-CTLA-4 antibodies[J]. Liver Cancer, 2019, 8(6): 413-426.
|